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Constitutive nuclear factor (NF)-jB activation in haemato-
logical malignancies is caused in several cases by loss of
function mutations within the coding sequence of NF-jB
inhibitory molecules such as IjBa or p100. Hut-78, a
truncated form of p100, constitutively generates p52 and
contributes to the development of T-cell lymphomas but the
molecular mechanism underlying this oncogenic potential
remains unclear. We show here that MMP9 gene expres-
sion is induced through the alternative NF-jB-activating
pathway in ﬁbroblasts and also on Hut-78 or p52
overexpression in ﬁbroblasts as well as in lymphoma cells.
p52 is critical for Hut-78-mediated MMP9 gene induction
as a Hut-78 mutant as well as other truncated NF-jB2
proteins that are not processed into p52 failed to induce the
expression of this metalloproteinase. Conversely, MMP9
gene expression is impaired in p52-depleted HUT-78 cells.
Interestingly, MLL1 and MLL2 H3K4 methyltransferase
complexes are tethered by p52 on theMMP9 but not on the
IjBa promoter, and the H3K4 trimethyltransferase activity
recruited on the MMP9 promoter is impaired in p52-
depleted HUT-78 cells. Moreover, MLL1 and MLL2 are
associated with Hut-78 in a native chromatin-enriched
extract. Thus, we identiﬁed a molecular mechanism by
which the recruitment of a H3K4 histone methyltransferase
complex on the promoter of a NF-jB-dependent gene
induces its expression and potentially the invasive potential
of lymphoma cells harbouring constitutive activity of the
alternative NF-jB-activating pathway.
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Introduction
Most haematological disorders remarkably share a
constitutive nuclear factor (NF)-kB activity (Karin
and Lin, 2002; Courtois and Gilmore, 2006; Keutgens
et al., 2006; Jost and Ruland, 2007; Perkins, 2007).
NF-kB is a latent cytoplasmic transcription factor whose
activation is regulated via control of nuclear transloca-
tion through the signal-induced degradation of inhibi-
tory proteins (Hayden and Ghosh, 2008). Two main
NF-kB-activating signalling pathways have been char-
acterized and referred to as the ‘classical’ or ‘canonical’
pathway and the ‘alternative’ or ‘non-canonical’ path-
way (Bonizzi and Karin, 2004). The classical pathway,
which is triggered by cytokines such as tumor necrosis
factor-a (TNFa), interleukin (IL)-1b, or by the ligand for
the T-cell or B-cell receptor, leads to IkBa degradation
and subsequent nuclear import of the p50/p65 hetero-
dimer through a NEMO/IKKg-dependent pathway (Li
and Verma, 2002; Shim et al., 2005). The alternative
pathway, which is triggered by cytokines such as
lymphotoxin-b (LTb), BAFF and CD40, relies on the
NIK- and IKKa-mediated phosphorylation and proces-
sing of the inhibitory protein p100 into p52. As a result, a
p52/RelB heterodimer moves into the nucleus and
induces the expression of proteins involved in lymphoid
organogenesis and B-cell homeostasis (Claudio et al.,
2002; Coope et al., 2002; Dejardin et al., 2002).
NF-kB acts as a survival factor from early lympho-
poiesis to later stage of development and maturation of
B and T cells (Siebenlist et al., 2005). The constitutive
NF-kB activity seen in most haematological disorders
occurs through several mechanisms, including the
chromosomal translocation and subsequent overexpres-
sion of BCL-3 in a subset of human B-cell chronic
lymphotic leukaemias (McKeithan et al., 1987) and
mutations of the IkBa gene that impair its inhibitory
function in some cases of Hodgkin’s lymphomas
(Cabannes et al., 1999; Emmerich et al., 1999; Jungnickel
et al., 2000). Gene ampliﬁcation of NIK or loss of
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function mutations for inhibitory signalling molecules
such as TRAF3 and CYLD have been reported in
multiple myelomas (Annunziata et al., 2007; Keats et al.,
2007).
Rearrangement of the nf-kb2 gene has been described
in some cutaneous T-cell lymphomas, B-cell chronic
lymphocytic leukemias (CLLs), multiple myelomas
and B-cell lymphomas (Keutgens et al., 2006). These
translocations cause the expression of truncated p100
proteins referred to as Lyt-10-Ca, LB40 or Hut-78/p85/
p80HT, that differ in their C-terminal end (Neri et al.,
1991; Fracchiolla et al., 1993; Thakur et al., 1994).
Those proteins are nuclear and constitutively generate
p52 because of the loss of the C-terminal processing-
inhibitory domain of p100 (Zhang et al., 1994;
Chang et al., 1995; Xiao et al., 2001). Mice with a
homozygous deletion of the C-terminal ankyrin repeats
of p100, which allows them to express p52 but not the
inhibitory protein p100, suffered from gastric hyperpla-
sia and also showed enlarged lymph nodes and increased
proliferation of peripheral lymphocytes (Ishikawa et al.,
1997). Interestingly, a transgenic mouse overexpressing
a lymphoma-associated NF-kB2 mutant Hut-78 in
lymphocytes developed small B-cell lymphomas, in part
through the upregulation of the antiapoptotic protein
TRAF1 (Zhang et al., 2007).
The progression of T-cell lymphoma towards a
metastatic phenotype is associated with the upregulation
of MMP9, which plays key roles in degradation of
extracellular matrix and in vascular remodelling (La-
lancette et al., 2000; Heissig et al., 2003). MMP9 is also
critical for B-CLL invasion and progression and has
been deﬁned as a prognostic factor in patients with non-
Hodgkin’s lymphoma (Sakata et al., 2004; Redondo-
Munoz et al., 2006). The transcriptional induction of
MMP9 is regulated by NF-kB in HTLV-I- or in
Epstein–Barr virus-infected cells (Yoshizaki et al.,
1998; Mori et al., 2002) as well as on TNFa stimulation
in skeletal muscle cells (Srivastava et al., 2007).
Although the classical, TAK1- and IKKb-dependent
NF-kB-activating pathway is required for the TNFa-
mediated MMP9 gene expression (Srivastava et al.,
2007), it is unclear whether the alternative NF-kB-
activating pathway is also involved in induction of
MMP9 in lymphoma cells.
Here we demonstrate that the constitutively
activated alternative NF-kB signalling pathway con-
tribute to the invasive potential of lymphoma cells
through induction of MMP9 gene expression by
tethering selected H3K4 methyltransferases in a
promoter-speciﬁc manner.
Results
Induction of MMP9 expression on p52 or Hut-78
overexpression in transformed ﬁbroblasts and in
lymphoma cells
To gain insight into the mechanisms underlying the
oncogenic potential of the truncated NF-kB2 precur-
sors, we overexpressed p52 or Hut-78 in NIH3T3 cells
through retroviral infections (Figure 1a), performed
microarray analysis and noticed that MMP9 was the
most strongly induced candidate (Figure 1b). IkBa gene
expression remained unchanged (data not shown) and
this candidate will be used as control for the subsequent
experiments. These data were conﬁrmed by Real-time
PCR analysis. Indeed, MMP9 but not IkBa gene
expression was induced on p52 or Hut-78 overexpres-
sion in NIH3T3 cells (Figure 1c). Although IkBa
expression on p52 or Hut-78 overexpression remained
unchanged, it was dramatically induced on TNFa
stimulation in control NIH3T3 cells (Figure 1d).
MMP9 activity was also induced as the gelatinase
activities of both p52 and Hut-78 overexpressing
NIH3T3 cells were enhanced compared to the ones
from control or NIH3T3 cells overexpressing p100HB,
another truncated p100 protein (Derudder et al., 2003)
which barely processes into p52 (Figure 1e, top panel,
compare lanes 2 and 3 with lanes 1 and 4, respectively).
Thus, MMP9 is a target gene of Hut-78 and p52 in
immortalized ﬁbroblasts. We next compared the ability
of two other truncated p100 proteins, LB40 and
p100HB, to induce the expression of this target gene.
Although MMP9 was also strongly induced in NIH3T3
cells overexpressing the p52-producing LB40 oncogenic
protein, p100HB did not induce MMP9 in those cells
(Figures 2a and b). We next generated a Hut-78 mutant
that failed to generate p52 because of the deletion of the
glycine-rich region (GRR) domain (‘Hut-78DGRR’;
Figure 2c, bottom panel, lane 5) and tested its ability
to drive MMP9 expression in NIH3T3 cells. This target
gene was weakly induced in those cells (Figure 2d),
indicating that MMP9 transcriptional induction occurs
through p52 overproduction. Importantly, the GRR
domain of p52 was required for MMP9 gene induction
as a p52 mutant lacking this region (‘p52 DGRR’;
Figure 2c, bottom panel, lane 3) failed to induce this
target gene (Figure 2d). Thus,MMP9 gene induction by
the truncated p100 proteins requires both their proces-
sing into p52 and the GRR domain.
To determine whether Hut-78-mediated MMP9 gene
induction also applies to lymphoma cells, we over-
expressed Hut-78 in the lymphoma-derived cell line
164T2. RelB and p50 levels remained similar to the ones
detected in control cells and only Hut-78 and p52 were
overexpressed (Figure 3a, top panel, compare lanes 1
and 2). There again, Hut-78 overexpression induced
MMP9 but not IkBa at the mRNA level (Figure 3b). We
next depleted p100/p52 through RNA interference in
HUT-78 cells and addressed MMP9 mRNA levels in
those lymphoma cells (Figure 3c, second panel from the
top, compare lanes 1 and 3 with lanes 2 and 4). MMP9
mRNA levels were decreased in those p52-depleted
HUT-78 cells (Figure 3d). We also looked at IkBa
protein levels and noticed that this product accumulated
in those p52-depleted cells, which indicates that p52 may
be required to repress the expression of IkBa in HUT-78
cells (Figure 3c, top panel). p52 depletion in HUT-78
cells also impaired their gelatinase activities, as evi-
denced by zymogram experiments (Figure 3e on the left,
compare lanes 1, 3 and 5 with lanes 2, 4 and 6,
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respectively). Importantly, MMP9 but not MMP2
protease activity was impaired on p52 depletion in
HUT-78 cells (Figure 3e, on the left, top and bottom
panels), which is in agreement with our microarray
results. The invasive potential of the p52-depleted
HUT-78 cells was also impaired, as evidenced by
Matrigel invasion assays (Figure 3e on the right).
Thus, our results demonstrate that MMP9 is a p52-
and Hut-78-dependent target gene in both transformed
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Figure 1 Induction ofMMP9 gene expression by p52 and Hut-78 in NIH3T3 cells. (a) Establishment of p52 or Hut-78 overexpressing
NIH3T3 cells through retroviral infections. NIH3T3 cells were infected with either an empty retroviral vector (pBabe, negative control)
or a retroviral construct expressing p52 or Hut-78, and cell extracts from those cells were subjected to anti-p100 or anti-b-actin western
blot analysis. (b) Induction of MMP9 gene expression on p52 or Hut-78 overexpression in NIH3T3 cells. Total RNAs extracted from
NIH3T3 cells infected with pBabe or with a p52 or Hut-78 expressing retrovirus were subjected to microarray analysis. The ﬁgure
shows microarray signal intensities from three distinct infections. Error bars denote standard deviation. (c) Induction of MMP9 but
not of IkBa gene expression on p52 or Hut-78 overexpression in NIH3T3 cells. Total RNAs from NIH3T3 cells infected with empty
pBabe, the p52 or Hut-78 expressing viruses were subjected to quantitative real-time PCR analysis to assess IkBa or MMP9 mRNA
levels using the appropriate primers. The abundance of the IkBa or MMP9 mRNA levels in NIH3T3 cells infected with the empty virus
was set to 1 and levels of both transcripts in p52 or Hut-78 overexpressing NIHT3 cells were relative to that after normalization with
glyceraldehyde-3-phosphate dehydrogenase (GAPDH). The ﬁgure shows the data from six independent experiments performed on two
distinct infections (mean values±s.d.). (d) Induction of IkBa expression on tumor necrosis factor-a (TNFa) stimulation but not on p52
overexpression in NIH3T3 cells. NIH3T3 infected with pBabe or with the p52 expressing retrovirus were left untreated or stimulated
with TNFa for the indicated periods of time and the abundance of the IkBa mRNA levels was assessed by Real-Time PCR analysis.
IkBa mRNA levels in untreated NIH3T3 cells infected with pBabe were set to 1 and levels of this transcript in the other experimental
conditions were relative to that after normalization with GAPDH. The ﬁgure shows the data from two independent experiments
performed in duplicates (mean values±s.d.). (e) p52 or Hut-78 overexpression in NIH3T3 cells enhances their gelatinase activities.
NIH3T3 cells were infected with the indicated retrovirus and zymograms were carried out using the supernatant from the infected cells
(upper panel). An anti-p100 western blot was performed using cell extracts from these infected NIH3T3 cells (bottom panel).
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p52 as a key molecule for the invasive potential of
lymphoma-derived cells harbouring enhanced NF-kB
activity.
MMP9 induction via both the classical and the alternative
NF-kB-activating pathways
To explore whether the alternative NF-kB-activating
pathway, which mainly relies on the p52/RelB hetero-
dimer, drives MMP9 expression, we ﬁrst stimulated
mouse embryonic ﬁbroblast (MEF) cells with a LTbR
agonistic antibody, which is known to trigger both the
classical and the alternative NF-kB-activating pathways
(Dejardin et al., 2002). As control, we stimulated those
cells with TNFa. As expected, the LTbR agonistic
antibody, but not TNFa, induced p100 processing into
p52 (Figure 4a, top panel, compare lane 2–4 with lane 1
and lanes 5–7 with lane 1). Both IkBa and MMP9 gene
expression were induced on TNFa or LTb stimulation,
although the kinetic of these inductions was different
(Figures 4c and d, respectively). We repeated those
experiments in NEMO-deﬁcient cells in which the
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Figure 2 MMP9 gene expression requires both constitutive p52 processing of the truncated oncogenic nuclear factor (NF)-kB2
proteins as well as the glycine-rich region (GRR) domain of p52. (a and b)MMP9 gene induction by the p52-producing and truncated
NF-kB2 proteins. (a) On the top, schematic representation of three distinct truncated NF-kB2 proteins (Hut-78, LB40 and p100HB).
At the bottom, cell extracts from NIH3T3 cells infected with the indicated retrovirus were subjected to anti-p100 and anti-b-actin
western blots. (b) Overexpression of both Hut-78 and LB40 but not p100HB triggers MMP9 gene expression. Total RNAs from
NIH3T3 cells infected with the indicated retrovirus were subjected to Real-Time PCR to assess MMP9 and IkBa expressions. MMP9
and IkBa mRNA levels in NIH3T3 cells infected with pBabe were set to 1 and levels of these transcripts in the other experimental
conditions were relative to that after normalization with glyceraldehyde-3-phosphate dehydrogenase (GAPDH). The ﬁgure shows the
data from three independent experiments performed in duplicates (mean values±s.d.). (c and d) MMP9 induction in NIH3T3 cells
requires p52 overproduction and the GRR domain of p52. C. On the top, schematic representation of both Hut-78 and p52 proteins
and a Hut-78 mutant that failed to generate p52 because of the deletion of GRR domain (‘Hut-78 DGRR’). The p52 DGRR mutant is
represented as well. At the bottom, cell extracts from NIH3T3 cells infected with the indicated retrovirus constructs were subjected to
anti-p100 and anti-b-actin western blot analysis. (d) Overexpression of the Hut-78 DGRR mutant does not trigger MMP9 gene
expression. Total RNAs from NIH3T3 cells infected with pBabe, p52, Hut-78 or with the Hut-78 DGRR or the p52 DGRR constructs
were subjected to real-time PCR to assess MMP9 and IkBa expressions. MMP9 and IkBa mRNA levels in NIH3T3 cells infected with
pBabe were set to 1 and levels of these transcripts in the other experimental conditions were relative to that after normalization with
GAPDH. The ﬁgure shows the data from three independent experiments performed in duplicates (mean values±s.d.).
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expected, LTb, but not TNFa, triggered p100 processing
into p52 in these NEMO-deﬁcient cells (Figure 4b, top
panel, compare lane 1 with lanes 2–7), which conﬁrmed
that the NF-kB-alternative pathway is still functional in
these cells. We observed that TNFa but not LTb-
mediated MMP9 and IkBa inductions of gene expres-
sion were severely impaired in the NEMO-deﬁcient
MEFs (Figures 4c and d). Thus, our data suggest that
MMP9 gene expression is regulated by the alternative
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Figure 3 MMP9 is a p52-dependent gene in lymphoma cells. (a and b) Hut-78 overexpression in a lymphoma cell line triggersMMP9
but not IkBa gene expression. (a) Cell extracts from the 164T2 cell line stably transfected with an empty vector or with a FLAG-tagged
Hut-78 expression plasmid (lanes 1 and 2, respectively) were subjected to western blot experiments using the anti-p100, anti-RelB, p50
or b-actin, as indicated. (b) Increased MMP9 but not IkBa mRNA levels on Hut-78 overexpression in 164T2 cells. MMP9 and IkBa
mRNA levels using total RNAs from both Hut-78 expressing or control 164T2 cells were quantiﬁed by real-time PCR analysis. The
ﬁgure shows the data from two independent experiments performed in duplicates and plotted as described above (mean values±s.d.).
(c) Establishment of p52-depleted HUT-78 cells. HUT-78 cells were infected with the indicated shRNA lentiviral construct and cell
extracts from these infected cells were subjected to anti-IkBa, anti-p100 and b-actin western blot analysis. The ﬁgure shows the data
obtained from two independent infections. (d) Decreased MMP9 mRNA levels on p52 depletion in HUT-78 cells. MMP9 mRNA levels
using total RNAs from HUT-78 cells infected with the control or with the shRNA p52 lentiviral construct were quantiﬁed by real-time
PCR analysis. MMP9 mRNA levels in HUT-78 cells infected with the control shRNA was set to 1 and levels of these transcripts in the
other experimental condition were relative to that after normalization with 18S. The ﬁgure shows the data from ﬁve independent
experiments performed in duplicates (mean values±s.d.). (e) Impaired gelatinase activity and invasive potential in p52-depleted HUT-
78 cells. On the left, conditional media from HUT-78 cells infected with the control shRNA or with the shRNA p52 for 24 or 48 h (top
and bottom panels, respectively) were subjected to zymogram experiments using a SDS-polyacrylamide gel copolymerized with
gelatine. The upper and lower bands correspond to MMP9 and MMP2 activities, respectively. On the right, HUT-78 infected with the
indicated shRNA constructs were subjected to Matrigel invasion assays and the number of migrating cells was plotted. The Figure
shows the representative results (mean values±s.d.) from two independent infections.
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Hut-78 interacts with multiple NF-kB/IkB proteins,
coactivators and corepressors
Transcriptional activators or coactivators should be
part of these Hut-78 or p52-containing transcriptional
complexes for the induction of MMP9 gene expression.
Immunoﬂuorescence studies indicated that Hut-78
and p52 were nuclear whereas p100 was cytoplasmic
(Figure 5b, top panels). A nuclear localization signal
(NLS; RKRRK, amino acids 337–341) was identiﬁed
within its Rel homology domain (RHD; Figure 5a; Neri
et al., 1991). To prove the role of this sequence for the
nuclear localization of Hut-78, we generated from one
(‘NLS 1’ to ‘NLS 5’) to 4 amino-acid substitutions (NLS
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Figure 4 Induction of MMP9 gene expression via the alternative nuclear factor (NF)-kB-activating signalling pathway. (a) p100
processing into p52 in lymphotoxin-b (LTb)-stimulated but not tumor necrosis factor-a (TNFa)-stimulated wild-type mouse
embryonic ﬁbroblast (MEF) cells. MEF cells were left untreated (lane 1) or stimulated with the indicated periods of time with a LTbR
agonistic antibody (lanes 2–4) or with TNFa (lanes 5–7) and cell extracts from those cells were subjected to anti-p100, anti-NEMO and
anti-b-actin western blot analysis, as indicated. (b) Unaltered LTb-mediated p100 processing into p52 in NEMO-deﬁcient MEF cells.
Same as in a. except that the treatments were performed on the NEMO-deﬁcient MEF cells. (c and d) LTb-mediated but not TNFa-
mediated transcriptional induction of MMP9 and IkBa in NEMO-deﬁcient MEF cells. Total RNAs from TNFa-stimulated (c) or
LTb-stimulated (d) wild-type or NEMO-deﬁcient cells were subjected to quantitative real-time PCR analysis to assess IkBa or MMP9
mRNA levels using the appropriate primers. The abundance of the IkBa or MMP9 mRNA levels in unstimulated cells was set to 1 and
levels of both transcripts in TNFa or LTb-stimulated cells were relative to that after normalization with glyceraldehyde-3-phosphate
dehydrogenase (GAPDH). The ﬁgure shows the data from three independent experiments (mean values±s.d.).
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localization of the resulting mutants by immunoﬂuor-
escence. Although amino acids 337 and 341 were
dispensable for the nuclear localization of Hut-78 as
both the ‘NLS1’ and ‘NLS5’ mutants were mostly
nuclear, amino acids 338 or 339 were essential as both
‘NLS 2’ and ‘NLS 3’ mutants were mostly cytoplasmic
(Figure 5b). Such staining was even more dramatic with
the ‘NLS 1,2,3,4’ mutant where amino acids 337–340
were substituted to alanine (Figure 5b). Mutation of this
NLS did not prevent the constitutive processing into p52
(Figure 5c, compare lanes 2 and 3). Thus, the nuclear
localization of Hut-78 requires the NLS sequence
located within the RHD.
We next selected and tested several nuclear NF-kB
proteins that harbour a transactivating domain for interac-
tion with Hut-78. p65 and RelB bound this truncated NF-
kB2 protein in HUT-78 cells (Figure 5d, top panel, lanes 3
and 4, respectively). Hut-78 was also found in the anti-p50
immunoprecipitate (Figure 5d, top panel, lane 2). More-
over, ectopically expressed FLAG-Hut-78 also bound
overexpressed BCL-3, another oncogenic member of the
IkB family that harbours two transactivation domains
(Bours et al., 1993; Figure 5e, top panel, lane 3). Thus, Hut-
78 interacts with multiple NF-kB proteins as well as HDAC
proteins (see Supplementary Data section) in the nucleus.
p52 and Hut-78-mediated MMP9 transcriptional
induction involves the recruitment of a H3K4 HMT
complex
Covalent modiﬁcations of histones control chromatin
structure and regulate gene expression (Shilatifard,
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Figure 5 Hut-78 interacts with multiple nuclear factor (NF)-kB proteins and requires a functional NLS located within the RHD
domain for its nuclear localization. (a) Schematic representation of wild-type NF-kB2/p100, Hut-78 and of Hut-78 mutants harbouring
from 1 (‘NLS 1’ to ‘NLS 5’) to 4 lysine to alanine substitutions (‘NLS 1234’) within the nuclear localization sequence (‘NLS’). RHD,
Rel homology domain; PID, processing inhibitory domain; DD, death domain. (b) Hut-78 is a nuclear protein and harbours a
functional NLS sequence. HeLa cells were transfected with 2mg of the indicated expression vectors and analysed by
immunoﬂuorescence using an antiserum recognizing the N-terminal peptide of NF-kB2/p100 as primary antibody and ﬂuorescein
isothiocyanate (FITC)-conjugated anti-mouse IG as secondary antibody. (c) Constitutive processing of Hut-78, Hut-78 NLS 1234 and
of the K75A mutant into p52. 293 cells were transfected with the indicated expression plasmids and an anti-p100 western blot was
carried out on the cell extracts. (d) Hut-78 binds to multiple NF-kB proteins. Cell extracts from HUT-78 cells were subjected to anti-
HA (negative control), -p50, -p65 or -RelB immunoprecipitations followed by anti-p100 western analysis (top panel, lanes 1–4,
respectively). Cell extracts were also subjected to anti-p100, -p50, -p65 or -RelB analysis as well (bottom panels). (e) Hut-78 binds BCL-
3. 293 cells were transfected with the indicated expression plasmids and anti-HA (negative control) or anti-BCL-3 immunoprecipita-
tions followed by anti-p100 western analysis were carried out on the cell extracts, as indicated (top panel). Cell extracts were subjected
to anti-p100 and anti-BCL-3 western analysis as well (bottom panels).
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lysine methylation is involved in both gene activation
and repression, depending on the identity of the lysine
residue targeted for methylation. As di- and trimethyla-
tion at histone H3 lysine 4 are correlated with gene
activation (Noma and Grewal, 2002; Santos-Rosa et al.,
2002), we determined whether histone H3 was trimethy-
lated at lysine 4 on the kB site of the MMP9 promoter
on p52 or Hut-78 overexpression by chromatin im-
munoprecipitation (ChIP) assays. A robust histone
H3K4 trimethylation was detected on the MMP9 but
not on the IkBa promoter on p52 or Hut-78 over-
expression in NIH3T3 cells (Figure 6b). This recruit-
ment relies on p52 production as a much weaker H3K4
histone methyltransferase (HMT) activity was detected
on the MMP9 promoter in cells expressing the Hut-78
DGRR mutant (Figure 6b). Finally, the H3K4me3
activity on the MMP9 promoter was impaired on p52
depletion in HUT-78 cells (Figure 6c). Thus, over-
expressed p52 and Hut-78 induce MMP9 expression by
tethering a H3K4 HMT complex.
Whereas one multi-subunit complex (referred to as
COMPASS and Set1 complex) that includes the
Drosophila trithorax-related protein Set1 has been
shown to trigger the mono-, di- and trimethylation of
histone H3K4 in yeast (Briggs et al., 2001; Miller et al.,
2001; Nagy et al., 2002; Noma and Grewal, 2002),
multiple complexes harbouring robust H3K4 HMT
activities have been isolated in mammalian cells and
all of them contained one or two SET domain-contain-
ing homologues of yeast Set1 (Hughes et al., 2004;
Glaser et al., 2006). As those distinct Set-1-like human
H3K4 HMT complexes also share common subunits
such as ASH2L, RBBP5 and WDR5, we determined
whether those proteins interact with p52 by coimmuno-
precipitation experiments. ASH2L bound p52, although
not as strongly as BCL-3 did (used as a positive control;
Figure 6d, top panel on the left, lanes 4 and 1,
respectively). In contrast to ASH2L, both RBBP5 and
WDR5 did not associate with p52 (Figure 6d, top panels
on the middle and the right, compare lanes 2 with lanes
4). To explore whether Hut-78 is associated with some
ASH2L-containing H3K4 HMTs at the endogenous
level, we reasoned that those proteins presumably
interacted in the chromatin. This was supported by the
nuclear colocalization of Hut-78 but not of Hut-78 NLS
1234 with ASH2L (Figure 6e, panels on the right). We
isolated the chromatin-associated proteins from HUT-
78 cells, performed anti-ASH2L, -MLL1 and -MLL2
immunoprecipitations and noticed that Hut-78 bound
ASH2L, MLL2 and to a less extent MLL1 (Figure 6f,
lanes 2, 4 and 3, respectively). Thus, our data
demonstrate that Hut-78 interacts with some H3K4
HMT complexes in the chromatin of HUT-78 cells.
To explore whether those H3K4 HMTs are recruited
by p52 on the MMP9 promoter, we investigated
MLL1 and MLL2 (also named KMT2A and KMT2B,
respectively; Allis et al., 2007) recruitments to this
p52-regulated target gene by ChIP assays. Although we
did not detect their recruitment on the IkBa promoter,
both MLL1 and MLL2 proteins were tethered on the
MMP9 promoter in p52 overexpressing NIH3T3 cells
(Figure 6g). Thus, our data suggest that p52 recruits
the H3K4 HMT MLL1 and MLL2 complexes in a
gene-speciﬁc manner.
Discussion
The NF-kB2 translocation ultimately causes the loss of
the inhibitory function of p100 and also p52 over-
Figure 6 Hut-78 and p52 recruit a H3K4 histone methyltransferase (HMT) on the kB site of the MMP9 promoter. (a) Schematic
representation of the promoter sequences of both MMP9 and IkBa murine genes. The nuclear factor (NF)-kB, AP1/2, Sp1 binding
sites and the TATA box are illustrated. The arrows indicate the primers used in chromatin immunoprecipitation (ChIP) assays. (b)
Recruitment of a H3K4 HMT activity on the MMP9 promoter via p52 and Hut-78. ChIP assays using an anti-H3K4me3 antibody
were performed on DNA extracts from NIH3T3 cells infected with the empty pBabe, or the retrovirus expressing p52, Hut-78 or the
Hut-78 DGRR mutant. Primers were derived from the promoter region of MMP9 or IkBa genes and were designed to amplify a
fragment that includes the kB sites. The recruitment of the H3K4me3 activity in the NIH3T3 cells infected with the empty pBabe
construct was set to 1 and its levels in the other conditions were relative to that after normalization with H3. The ﬁgure shows the data
from three independent experiments performed in duplicates (mean values±s.d.). (c) Impaired recruitment of the H3K4me3 activity in
p52-depleted HUT-78 cells. ChIP assays on HUT-78 cells infected with the indicated shRNA construct were carried out using an anti-
H3K4me3 antibody. The signal obtained from a noncoding region (downstream of the albumin gene (Kouskouti and Talianidis, 2005))
was used to compensate for possible ﬂuctuations arising during handling. The H3K4 me3 ChIP values in HUT-78 cells infected with
the control shRNA construct was set to 1 and its value in the HUT-78 cells infected with the shRNA p52 was relative to that after
normalization with the total H3 signal (as detected using the corresponding anti-H3 antibody). The ﬁgure shows the data obtained
from ﬁve independent experiments performed on two distinct infections (means±s.d.). (d) Association of p52 with ASH2L but not
with RBBP5 and WDR5. 293 cells were transfected with the indicated expression plasmids and anti-FLAG immunoprecipitates
followed by anti-p100 western blot analysis were carried out on the cell extracts (top panels). Anti-p100 and anti-FLAG western blots
were performed on the crude cell extracts as well (bottom panels). (e) Hut-78 but not Hut-78 NLS 1234 colocalizes with ASH2L in the
nucleus. HeLa cells were transfected with the indicated expression plasmids and anti-p100 or anti-HA immunoﬂuorescences were
carried out to detect Hut-78, Hut-78 NLS 1234 or ASH2L, respectively. (f) Association of Hut-78 with MLL1 and MLL2 in native
chromatin-enriched extracts. Chromatin-associated proteins were isolated from highly puriﬁed and intact nuclei of HUT-78 cells
(40 106 cells per experimental condition), as described (Aygun et al., 2008) and anti-HA (negative control), -ASH2L,
-MLL1 and -MLL2 immunoprecipitates were carried out from those extracts, using the corresponding antibodies, followed by an
anti-p100 western blot (panel on the left, lanes 1–4, respectively). Cell extracts were also subjected to anti-p100 western blot analysis
(right panel). (g) Enhanced MLL1 and MLL2 recruitments to theMMP9 but not the IkBa promoter on p52 overexpression in NIH3T3
cells. ChIP assays using an anti-MLL1 or anti-MLL2 antibody were performed on DNA extracts from NIH3T3 cells infected with the
empty pBabe, or the retrovirus expressing p52. The recruitment of MLL1 or MLL2 in the NIH3T3 cells infected with the empty pBabe
construct was set to 1 and its levels in the other conditions were relative to that after normalization with H3. The Figure shows the data
from three (MLL1) or two (MLL2) independent experiments performed in duplicates (mean values±s.d).
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production. Although there is now experimental evi-
dence for a key role of this chromosomal translocation
in lymphomagenesis (Zhang et al., 2007), it remained
unclear whether the loss of the inhibitory function of
p100 and/or the overproduction of p52 is the underlying
mechanism. There are several evidences for p52 being
essential for the oncogenic potential of the truncated
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mutant that constitutively produces p52 are oncogenic
in vitro, as judged by colony-formation assays per-
formed in rat embryonic ﬁbroblasts or in mouse FL5.12
cells (Qing et al., 2007). These data suggest that p52
overproduction is sufﬁcient to trigger a transformation
anchorage-independent growth in those cells and this
was further supported by the very similar expression
proﬁle of many tumour-associated genes on overexpres-
sion of either p52 or the truncated p100 product (Qing
et al., 2007). Our data support the notion that many
tumour-associated genes are induced by the NF-kB2
truncated proteins via p52 production as MMP9 is
similarly induced by p52 or Hut-78 but not by a mutant
defective in processing. Nevertheless, other data chal-
lenged the notion that p52 overproduction alone drives
lymphomagenesis. Indeed, constitutive production of
p52 in lymphocytes is not tumorigenic in mice but rather
predisposed to an inﬂammatory autoimmune disease
through a sustained repression of Bim, a member of
the antiapoptotic Bcl-2 family (Wang et al., 2008). In
contrast to Hut-78, overexpressed p52 only transiently
induced TRAF1 expression in lymphocytes and rather
appeared to act as homodimers harbouring repressing
transcriptional activities in vitro and in vivo (Wang et al.,
2008). Those data are in agreement with earlier studies
showing that Hut-78 harboured an enhanced transacti-
vation potential compared to p52 (Chang et al., 1995;
Epinat et al., 2000; Kim et al., 2000). Thus, over-
produced p52 in lymphocytes triggers the expression of
many common target genes, among which is MMP9,
yet several genes such as TRAF1 required to drive
lymphomagenesis in vivo are speciﬁcally induced by
Hut-78 but not by p52.
The enhanced MMP9 expression seen on p52 over-
production highlights the fact that the constitutively
activated alternative NF-kB pathway contributes to
the pathogenesis of haematological disorders such as
multiple myelomas and cutaneous T-cell lymphomas
(Annunziata et al., 2007; Keats et al., 2007). In support
for a role of this pathway in lymphomagenesis, NIK is
overexpressed in some cases of T-cell leukaemias and
in Hodgkin’s lymphomas that do not express any
oncogenic viral proteins (Saitoh et al., 2008). Levels of
p52 are also increased in those NIK overexpressing
haematological disorders and levels of MMP9 are
decreased on NIK depletion through RNAi interference
in these cells (Saitoh et al., 2008). Thus, these data,
combined with our report, suggest that MMP9 is a
direct target gene of the NIK- and p100/p52-dependent
signalling cascade.
Coactivators could be recruited by NF-kB/IkB
proteins on selected promoters. Indeed, we demon-
strated that overproduced p52 induces gene transcrip-
tion by recruiting selected H3K4 HMT in a promoter-
speciﬁc manner. Indeed, whereas p52 tethers MLL1 and
MLL2 complexes on theMMP9 gene promoter, it failed
to do it on the IkBa promoter in NIH3T3 cells. This
mechanism may explain why p52 signiﬁcantly induces
MMP9 but not IkBa gene expression in these cells. Our
data indeed suggest that the differential recruitment of
H3K4 HMT complexes by NF-kB proteins will govern
the ability of those target genes to be induced or not by
those transcription factors. Several potential mechan-
isms underlying the recruitment of H3K4 HMT com-
plexes to the target genes were discussed (Ruthenburg
et al., 2007). One hypothesis is the direct recruitment of
H3K4 HMT complexes to selected promoters by the
DNA binding factors whereas the MLL core complex
components (WDR5, RBBP5 and ASH2L) would
regulate the activity but not the recruitment of those
enzymatic complexes to their target loci. Our data
favour this hypothesis as we show here that a Hut-78
mutant that does not generate p52 did not efﬁciently
drive MMP9 gene expression, at least in part because it
failed to properly recruit an H3K4me3 enzymatic
activity on the promoter of this gene. Our data highlight
a promoter-speciﬁc recruitment of selected H3K4 HMT
complexes by an oncogenic NF-kB/IkB protein, yet the
molecular mechanisms underlying this gene-speciﬁc
effect remains totally unknown. It will be of great
interest to experimentally address to which extent the
post-translational modiﬁcations of the NF-kB/IkB
proteins themselves in response to various signals
ultimately regulate the ability of those transcription
factors to recruit H3K4 HMT complexes on the
promoters of their target genes.
H3K4 me3 is a dynamic modiﬁcation (Berger, 2007)
and a family of proteins sharing the Jumonji C (JmjC)
domain were showed to catalyse site-speciﬁc demethyla-
tion of mono-, di- and trimethylated histones (Klose
et al., 2006). Among them is RBP2, a demethylase that
speciﬁcally catalyses demethylation on H3K4 (Klose
et al., 2007). Whether this demethylase regulates the
expression of the NF-kB target genes remains an open
question but our data strongly suggest that the
recruitment of NF-kB proteins that positively regulate
gene transcription may involve the concomitant removal
of H3K4 demethylases from the promoter of those NF-
kB-dependent genes. Importantly, the H3K27 demethy-
lase Jmjd3 whose inducible expression in lipopolysac-
charide-stimulated macrophages is NF-kB dependent
was found associated with WDR5 and RBBP5, the core
subunits of the H3K4 HMT MLL complexes, a result
that support the existence of a functional cross-talk
between changes in H3K4me3 and H3K27me3 (De
Santa et al., 2007). This study, combined with our
report, opens unexplored avenues of research whose
goal will be to deﬁne the contribution of those lysine-
speciﬁc demethylases in the regulation of NF-kB target
genes in health and in diseases.
Materials and methods
Cell culture, biological reagents and treatments
Human embryonic kidney 293, HeLa and NIH3T3 cells as well
as wild-type or NEMO-deﬁcient immortalized mouse embryo-
nic ﬁbroblasts, a gift from Dr M Pasparakis (Institute for
Genetics, Centre for Molecular Medicine (CMMC), University
of Cologne, Germany), were maintained in Dulbecco’s
modiﬁed Eagle’s medium supplemented with 10% fetal calf
serum (FCS; Life Technologies, Grand Island, NY, USA),
glutamine and antibiotics. HUT-78 cells were cultured in
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RPMI medium supplemented with 10% FCS, glutamine and
antibiotics. The lymphoma cell line 164T2, a gift from Dr Y
St-Pierre (INRS-Institut Armand-Frappier, University of
Que´bec, Laval, Que´bec, Canada), was cultured as described
(Aoudjit et al., 1998). TNFa was from Roche Applied Sciences
(Indianapolis, IN, USA) whereas the generation of the LTbR
agonistic antibody was previously described (Dejardin et al.,
2002).
Details on expression constructs and antiserum sources are
described in Supplementary Data.
Immunoprecipitations, immunofluorescences and isolation of
enriched native chromatin extracts
Immunoprecipitations in 293 cells were carried out as
previously described (Viatour et al., 2003). For immunoﬂuor-
escence studies, HeLa cells were seeded in six-well plates and
subsequently transfected with the indicated expression plas-
mids using FUGENE 6 (Roche). Twenty-four hours later, cells
were washed with phosphate-buffered saline, ﬁxed with 4%
paraformaldehyde and permeabilized with ethanol for 6min at
20 1C. Fixed cells were incubated with monoclonal anti-p100
antibodies for 45min at 371C followed by a 45min incubation
at RT with ﬂuorescein isothiocyanate-conjugated anti-mouse
immunoglobulin G (Dako, Glostrup, Denmark). Coverslips
were then mounted with Prolong Gold Antifade (Invitrogen,
Carlsbad, CA, USA) and cells were observed by ﬂuorescent
microscopy (Nikon).
Preparation of enriched native chromatin extracts from
HUT-78 cells were carried out as described (Aygun et al.,
2008).
Retroviral and lentiviral infections of NIH3T3 and HUT-78 cells
Retroviral infections of NIH3T3 cells were performed as
described (Viatour et al., 2004). For lentiviral infections
of HUT-78 cells, 293FT cells were transfected with 12mg of
the ‘non-target’ lentiviral shRNA plasmid (used as negative
control) or the shRNA construct that targets p100/p52
(NM_002502.2) with the following sequence 50-CCGG
CCCTATCACAAGATGAAGATTCTCGAGAATCTTCAT
CTTGTGATAGGGTTTTT-30 and with 12 and 5 mg of R8.91
and VSVG plasmids, respectively. The supernatants from
those infected cells were collected 48 h after transfection, added
with polybrene to 5 105 HUT-78 cells and subjected to
centrifugation for 10min at 1200 r.p.m. This later step was
repeated the next day and HUT-78 cells were treated with
puromycine (1 mg/ml) 48 h after the last infection.
Zymograms
Conditioned media of cells incubated in serum-free RPMI for
24 or 48 h were collected and centrifuged. Supernatant (18 ml)
mixed with 6ml of loading buffer were applied onto a 10%
polyacrylamide gel copolymerized with gelatin (1mg/ml).
After electrophoresis, gels were renatured in 2% Triton X-
100 for 1 h and incubated overnight at 37 1C in a buffer
consisting of 50mM Tris-HCl (pH7.6) and 10mM CaCl2. The
gels were then stained with Coomassie brilliant blue in 40%
methanol and 10% acetic acid and destained in 20% methanol
and 10% acetic acid. Gelatinase activities were detected as
transparent bands on the blue background.
Matrigel invasion assay
The assay was performed using a 24-well polycarbonate
transwell permeable support with 8mm pores (Corning
Costar), coated with 6.21mg of Matrigel (BD Biosciences,
Bedford, MA, USA). HUT-78 cells infected with distinct
shRNA constructs were suspended in serum-free RPMI at a
concentration of 5.105 cells/ml and 100ml were loaded into top
chambers. The lower chambers were ﬁlled with 0.6ml RPMI
containing 10% fetal bovine serum. After 72 h of incubation at
37 1C in a humidiﬁed 5% CO2 incubator, cells that migrated
through the Matrigel-coated ﬁlters were recovered from the
lower compartment and counted using a Thoma hemo-
cytometer.
Affymetrix microarray analysis
Total RNAs were extracted from NIH3T3 cells stably infected
with empty virus or virus expressing p52 or Hut-78 and
cultured in triplicates, using the RNeasy Minit kit from Qiagen
(Valencia, CA, USA). The integrity of the RNAs from those
nine distinct experimental conditions was checked with the
Agilent Bioanalyzer using the RNA 6000 Nano kit (Agilent,
Santa Clara, CA, USA). Biotin-labelled cRNA and subsequent
hybridization and scanning were performed following the
manufacturer’s instructions.
Real-Time PCRs and ChIP assays
Total RNAs were extracted using the EZNA Total RNA kit
(Omega Bio-tek, Norcross, GA, USA) and cDNAs were
synthesized using the RevertAid H Minus First Strand cDNA
Synthesis kit (Fermentas, Glen Burnie, MD, USA). Subsequent
PCRs were carried out using the Power SYBR Green PCR
master kit (Applied Biosystems, Foster City, CA, USA) on the
LightCycler 480 (Roche). Primers to amplify IkBa and MMP9
sequences from NIH3T3 and HUT-78 cells as well as for the
ampliﬁcation of glyceraldehyde-3-phosphate dehydrogenase
and 18S sequences (for normalization purposes in NIH3T3
and HUT-78 cells, respectively) are available on request.
For ChIP assays, cells were cross-linked with 1% parafor-
maldehyde and sonicated using the Bioruptor (Diagenode).
ChIP assays were performed using the OneDay ChIP kit
(Diagenode) using 1.5–2 106 cells per experimental condition.
Subsequent PCRs were carried out using the Power SYBR
Green PCR master kit (Applied Biosystems) on the Light-
Cycler 480 (Roche). Input DNA was analysed simultaneously
and used as normalization. For normalization of the ChIP
assays in HUT-78 cells, the signal obtained from a non-coding
region (downstream of the albumin gene (Kouskouti and
Talianidis, 2005) was used to compensate for possible
ﬂuctuations arising during handling. For the histone-related
ChIPs, H3K4me3 ChIP values were normalized according to
the total H3 signal (as detected using the corresponding anti-
H3 antibody).
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